Enanta Pharmaceuticals, Inc. (ENTA): Price and Financial Metrics
ENTA Price/Volume Stats
| Current price | $12.36 | 52-week high | $55.00 |
| Prev. close | $12.26 | 52-week low | $8.08 |
| Day low | $11.01 | Volume | 436,600 |
| Day high | $12.50 | Avg. volume | 296,267 |
| 50-day MA | $10.76 | Dividend yield | N/A |
| 200-day MA | $15.92 | Market Cap | 261.49M |
ENTA Stock Price Chart Interactive Chart >
ENTA POWR Grades
- Value is the dimension where ENTA ranks best; there it ranks ahead of 72.29% of US stocks.
- ENTA's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
- ENTA ranks lowest in Stability; there it ranks in the 15th percentile.
ENTA Stock Summary
- Of note is the ratio of ENANTA PHARMACEUTICALS INC's sales and general administrative expense to its total operating expenses; only 10.15% of US stocks have a lower such ratio.
- The ratio of debt to operating expenses for ENANTA PHARMACEUTICALS INC is higher than it is for about just 16.06% of US stocks.
- In terms of volatility of its share price, ENTA is more volatile than 93.72% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to ENANTA PHARMACEUTICALS INC, a group of peers worth examining would be AEVA, BOLT, STRO, CRBU, and RGNX.
- Visit ENTA's SEC page to see the company's official filings. To visit the company's web site, go to www.enanta.com.
ENTA Valuation Summary
- ENTA's price/earnings ratio is -1.5; this is 105.15% lower than that of the median Healthcare stock.
- ENTA's price/sales ratio has moved down 1.7 over the prior 131 months.
Below are key valuation metrics over time for ENTA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ENTA | 2023-12-29 | 2.5 | 0.9 | -1.5 | -1.1 |
| ENTA | 2023-12-28 | 2.6 | 0.9 | -1.5 | -1.1 |
| ENTA | 2023-12-27 | 2.6 | 0.9 | -1.5 | -1.1 |
| ENTA | 2023-12-26 | 2.5 | 0.9 | -1.5 | -1.1 |
| ENTA | 2023-12-22 | 2.4 | 0.9 | -1.4 | -1.0 |
| ENTA | 2023-12-21 | 2.4 | 0.9 | -1.4 | -1.0 |
ENTA Growth Metrics
- The 5 year revenue growth rate now stands at 280.71%.
- Its 5 year net cashflow from operations growth rate is now at 1030.77%.
- Its year over year price growth rate is now at 11.1%.
The table below shows ENTA's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-12-31 | 82.097 | -107.152 | -120.626 |
| 2022-09-30 | 86.16 | -84.782 | -121.755 |
| 2022-06-30 | 89.418 | -90.269 | -120.006 |
| 2022-03-31 | 91.563 | -90.173 | -112.33 |
| 2021-12-31 | 92.979 | -68.377 | -100.783 |
| 2021-09-30 | 97.074 | -69.996 | -78.996 |
ENTA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ENTA has a Quality Grade of C, ranking ahead of 57.4% of graded US stocks.
- ENTA's asset turnover comes in at 0.206 -- ranking 196th of 682 Pharmaceutical Products stocks.
- GILD, ALT, and RDUS are the stocks whose asset turnover ratios are most correlated with ENTA.
The table below shows ENTA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.206 | 1 | -0.234 |
| 2021-03-31 | 0.193 | 1 | -0.207 |
| 2020-12-31 | 0.204 | 1 | -0.157 |
| 2020-09-30 | 0.242 | 1 | -0.083 |
| 2020-06-30 | 0.296 | 1 | -0.048 |
| 2020-03-31 | 0.354 | 1 | 0.017 |
ENTA Price Target
For more insight on analysts targets of ENTA, see our ENTA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $65.33 | Average Broker Recommendation | 1.7 (Moderate Buy) |
Enanta Pharmaceuticals, Inc. (ENTA) Company Bio
Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses a chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. The company was founded in 1995 and is based in Watertown, Massachusetts.
Latest ENTA News From Around the Web
Below are the latest news stories about ENANTA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ENTA as an investment opportunity.
The Zacks Analyst Blog Highlights Enanta, OneConnect Financial, KNOT Offshore, Hippo Holdings and H WorldEnanta, OneConnect Financial, KNOT Offshore, Hippo Holdings and H World are included in this Analyst Blog. |
Insider Sell Alert: Director Terry Vance Sells 15,295 Shares of Enanta Pharmaceuticals Inc (ENTA)In a notable insider transaction, Director Terry Vance has parted with 15,295 shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA), a significant move that warrants a closer look by investors and market analysts. |
Wall Street Analysts Predict a 108.12% Upside in Enanta Pharmaceuticals (ENTA): Here's What You Should KnowThe average of price targets set by Wall Street analysts indicates a potential upside of 108.1% in Enanta Pharmaceuticals (ENTA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
How Much Upside is Left in Enanta Pharmaceuticals (ENTA)? Wall Street Analysts Think 88.23%The mean of analysts' price targets for Enanta Pharmaceuticals (ENTA) points to an 88.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx ConferenceWATERTOWN, Mass., November 22, 2023--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at Evercore ISI HealthCONx Conference on November 29, 2023 at 7:55 a.m. ET in Miami, FL. |
ENTA Price Returns
| 1-mo | 4.13% |
| 3-mo | 49.64% |
| 6-mo | -22.22% |
| 1-year | -76.53% |
| 3-year | -77.51% |
| 5-year | -86.36% |
| YTD | 31.35% |
| 2023 | -79.77% |
| 2022 | -37.79% |
| 2021 | 77.62% |
| 2020 | -31.85% |
| 2019 | -12.78% |
Continue Researching ENTA
Want to do more research on Enanta Pharmaceuticals Inc's stock and its price? Try the links below:Enanta Pharmaceuticals Inc (ENTA) Stock Price | Nasdaq
Enanta Pharmaceuticals Inc (ENTA) Stock Quote, History and News - Yahoo Finance
Enanta Pharmaceuticals Inc (ENTA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...